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Abstract
Objective. To assess patients with SSc who present without circulating ANAs or RP.
Methods. Five thousand three hundred and ninety patients who fulfilled the ACR criteria for SSc and were
enrolled in the EULAR Scleroderma Trials and Research (EUSTAR) database were screened for the ab-
sence of both RP and circulating ANA. To differentiate SSc from its mimics, additional information was
gathered using a standardized questionnaire.
Results. Five thousand three hundred and seventy-eight (99.8%) of the 5390 SSc patients in the EUSTAR
database had either detectable ANA or a history of RP. Twelve (0.2%) patients lacked both circulating ANA
and RP. Details of the medical history could be obtained for seven patients. Three cases were compatible with
ANA-negative and RP-negative SSc and were not typical of any known SSc mimic. Four patients had a malig-
nancy: two had breast cancer, one had multiple myeloma with possible scleromyxoedema and one had bladder
carcinoma. There was no temporal relationship between the onset of skin fibrosis and that of the tumour. Although
no patient with confirmed nephrogenic systemic fibrosis was identified among the cases of ANA-negative and
RP-negative SSc, the presentation of one patient could be compatible with that of nephrogenic systemic fibrosis
other than for the absence of chronic kidney disease or of known prior gadolinium exposure.
Conclusion. We have identified a very small subgroup of SSc patients who lack both circulating ANA and
RP, none of whom fulfils the diagnostic criteria for any known SSc mimic. Prospective studies are needed
to elucidate the clinical presentation, evolution and outcome of such patients.
Key words: systemic sclerosis, scleroderma, nephrogenic systemic fibrosis, scleromyxedema, eosinophilic
fasciitis, ANA, Raynaud’s phenomenon, digital ulcers, differential diagnosis.
Introduction
SSc is an autoimmune disease in which vascular and im-
munological processes lead to progressive organ fibrosis
[1]. Prominent early features of the disease include circu-
lating ANAs as a marker of immunological abnormalities
and RP, which often results in digital ulceration, as a sign
of vascular dysfunction. Circulating ANAs are detected in
more than 90% of SSc cases [2], and the prevalence of
RP has been as high as 98% in some studies [3]. There is
a single report of a patient with SSc, but without RP or
circulating ANA [4]. However, it has not yet been deter-
mined whether this individual might epitomize a subgroup
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of patients with SSc who lack both RP and circulating
ANA.
The presence of cutaneous fibrosis without RP or circu-
lating ANA should always prompt the search for an alter-
native diagnosis. The differential diagnosis of hardened
and thickened skin includes several SSc mimics, among
which are nephrogenic systemic fibrosis (NSF), scleromyx-
oedema, eosinophilic fasciitis, pansclerotic morphea and
scleroedema adultorum (of Buschke) [5, 6]. Differentiation
among these entities is facilitated by assessment of phys-
ical findings, laboratory testing, skin biopsy and nail-fold
capillaroscopy (Table 1). Despite these additional investi-
gations, some patients with sclerotic skin may still be mis-
classified as having SSc, even by expert rheumatologists.
This is exemplified by NSF, a newly evolved disease that
produces an SSc phenotype [7, 8]. The objective of this
study was to assess the prevalence of SSc mimics in a
large cohort of patients fulfilling the ACR criteria for SSc
[9], but lacking both RP and circulating ANA.
Patients and methods
We conducted this study in the multicentre prospective
cohort of the EULAR Scleroderma Trials and Research
(EUSTAR) group. The structure of the EUSTAR database
has been published [10]. As per EUSTAR requirements,
every patient followed in the EUSTAR must have a signed
consent form and each centre must have obtained local
ethics committee approval. Adult patients registered in
the EUSTAR database as of December 2007 and fulfilling
the ACR criteria for SSc [9] were analysed. Subjects were
included in this subcohort if they never had RP and if they
also tested negative for ANA at any of the annual visits.
Because none of the scleroderma mimics typically is
associated with digital ulcers (DUs), the presence of a
DU at any of the annual visits excluded a subject from
this subcohort.
Centres that had patients meeting these criteria were
invited to complete a standardized questionnaire in
which they were asked to confirm the presence of SSc
and the absence of RP and ANA, and to provide additional
information on clinical details not regularly captured in the
EUSTAR database (e.g. the temporal onset of skin
changes, the distribution of skin involvement and findings
on nail-fold capillaroscopy). In particular, we also tried to
identify patients who might have NSF by enquiring about
the presence of chronic kidney disease and any exposure
to gadolinium-containing contrast agents (GCCAs) in re-
lation to disease onset [7, 11]. Because of the association
with scleromyxoedema, we also inquired about parapro-
teinaemia and the presence of mucin in skin histology
(Table 1). The questionnaire also asked about any history
of cancer, medical treatment, response to treatment and
clinical outcome.
Results
At the date of census in December 2007, 5390 adult pa-
tients who met the ACR criteria for SSc were enrolled in
EUSTAR. Of these, 5378 (99.8%) patients had either
detectable circulating ANA or a history of RP; 12 (0.2%)
of the 5390 patients had neither RP nor ANA. Although we
had specified that subjects would be excluded from the
subcohort if they had a DU, no patient with the absence of
both ANA and RP had any digital ulceration.
Completed questionnaires provided additional medical
information about 7 of the 12 patients without either RP or
circulating ANA, but no additional information could be
obtained from the remaining 5 cases. We were unable to
obtain consent from one female patient who was lost to
follow-up, therefore her detailed medical data have not
been included. Demographic characteristics of the
seven patients are presented in Table 2. Eight (66.7%)
of the 12 patients without RP or ANA presented with a
phenotype compatible with diffuse SSc, as compared
with only 38% of the patients in the remaining EUSTAR
population. There was a trend towards shorter disease
duration and higher modified Rodnan skin score (mRSS)
among the patients without RP or ANA, but this was not
statistically significant.
Although 5 of the 12 patients without RP or ANA had
been lost to follow-up, we were able to obtain limited
medical information about them. All had serum creatinine
levels within the normal range and none had been diag-
nosed with chronic kidney disease. Only one of these five
patients had undergone a GCCA-enhanced MRI examin-
ation. We present the individual cases of the six patients
without RP or ANA for whom data were available and
consent was provided, and their differential diagnoses
are discussed.
Case 1
A 63-year-old white woman had a mastectomy at the age
of 47 to treat breast cancer, without subsequent recur-
rence after local irradiation. At the age of 57, she noticed
a small pruritic morphea plaque on the abdomen and vis-
ited a dermatologist. Local treatment with a betametha-
sone was begun. Four months later she developed
sclerodactyly, as well as tightness and non-pruritic indur-
ation of the forearms and the perioral skin, characteristic
of SSc. She had never been exposed to gadolinium or
environmental toxins known to cause skin fibrosis, includ-
ing chemotherapeutic agents [12]. Within 2 months of the
onset of skin changes, her mRSS progressed from 15 to
27. She exhibited facial involvement with microstomia,
moderate skin thickening on her forearms and hands
with sclerodactyly, mild skin thickening on her upper
arms and distal thighs and severe skin thickening on her
legs and feet. The skin on her hands, distal forearms and
feet was oedematous and there was polyarticular joint
swelling. She had NYHA (New York Heart Association)
stage II dyspnoea due to mild interstitial lung disease
with ground glass opacifications and there also was
thickening of her oesophageal wall. She had mild periph-
eral blood eosinophilia (along with mild elevations of other
peripheral blood leucocytes, including neutrophils,
lymphocytes and monocytes). Nail-fold capillaroscopy
was normal (Fig. 1a). Biopsy of the involved abdominal
skin demonstrated severe dermal fibrosis, thickened s.c.
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septae and sparse perivascular lymphocytic inflammation
without eosinophils or mucin deposition (Fig. 1b and c).
Five months after the onset of skin changes, treatment
was initiated with low-dose daily oral prednisolone and
monthly i.v. pulses of CYC. With treatment, her mRSS
decreased from 27 to 12 and her forced vital capacity
(FVC) improved from 80 to 90% of predicted; however,
the DLCO (diffusion capacity of the lung for carbon mon-
oxide) remained within normal limits (93%). Prednisolone
was tapered and discontinued. Weekly oral MTX treat-
ment was initiated and, 4 years after the onset of skin
changes, her mRSS decreased to 3. Her dyspnoea
resolved and she was able to dance for hours. Because
she experienced arthralgias after each dose, MTX was
subsequently tapered and discontinued. Six months
after stopping MTX, a relapse of polyarthritis was treated
with SSZ and low-dose prednisolone. At age 62 years, her
mRSS remained at 3 and the 6-minute walk test (6 MWT)
was 558 m without oxygen desaturation. Nail-fold capil-
laroscopy revealed no scleroderma pattern.
The primary diagnostic considerations in this patient
had been eosinophilic fasciitis, a paraneoplastic syn-
drome and nephrogenic systemic fibrosis. She had per-
ipheral blood eosinophilia; however, the absence of an
eosinophilic infiltrate in her skin biopsy and the presence
of interstitial lung disease go against a diagnosis of eo-
sinophilic fasciitis. Also, there were no signs of recurrent
malignancy. The absence of skin changes on her face and
of mucin deposition in her skin biopsy is inconsistent with
scleromyxoedema or scleroedema adultorum. Without
prior gadolinium exposure, NSF would be unlikely; how-
ever, patients can be unaware of imaging studies during
which GCCA is administered. This patient most likely rep-
resents a true case of ANA-negative and RP-negative SSc
or of another systemic autoimmune disease with SSc
overlap [4].
Case 2
A 53-year-old white woman noted the onset of skin
thickening on her trunk. She also experienced joint pain
and contractures, episodic swelling of her hands and
muscle weakness and atrophy. Concurrently with the
onset of skin thickening, she observed a tumour in her
right breast and underwent a mastectomy for ductal car-
cinoma. She denied exposure to any toxins. Her skin
sclerosis was itchy, symmetrical and involved most
parts of her body, but spared her hands and feet
(Fig. 2). The skin of the abdomen, thighs and upper
arms had a peau d’orange appearance. Over time she
developed severe contractions. Her mRSS was 17. Nail-
fold capillaroscopy revealed avascular areas. There was
no peripheral blood eosinophilia or paraproteinaemia.
A skin biopsy from her left forearm showed increased mel-
anin in the stratum germinativum with a discrete diffuse
lymphocytic infiltrate in the dermis and extensive collagen
fibres without mucin deposition. Borrelia burgdorferi infec-
tion was excluded by serologic testing.
TABLE 2 Clinical characteristics of the study population
Clinical feature
Negative for all of RP, ANA and DU
Remaining SSc
patients
(n=5378), %Analysed (n=7), %
Additional data not
retrievable (n=5), %
ACR criteria positive 100.0 100.0 100
RP positive 0.0 0.0 96.3
ANA positive 0.0 0.0 92.3
DU positive 0.0 0.0 35.0
Age, mean (S.D.), years 48.8 (12.9) 66.8 (11.3) 57.8 (13.7)
SSc duration, mean (S.D.), months 67.0 (60.5) 76.1 (43.9) 175.1 (133.1)
mRSS, mean (S.D.) 23.8 (9.1) 21.2 (5.2) 11.8 (9.2)
DSSc 71.4 60.0 38.0
LSSc 28.6 40.0 57.5
ACA positive 0.0 0.0 30.4
Scl-70 positive 0.0 0.0 36.4
Elevated acute phase reactants 28.6 80.0 32.4
Proteinuria 14.3 0.0 6.2
Active disease 42.9 20.0 34.0
Synovitis 14.3 0.0 17.0
Joint contractures 71.4 20.0 34.3
Oesophageal involvement 42.9 20.0 68.6
Lung fibrosis (by chest X-ray) 14.3 20.0 22.6
Dyspnoea 14.3 0.0 37.9
Lung fibrosis 28.6 40.0 35.7
Arterial hypertension 14.3 0.0 18.9
Pulmonary hypertension 14.3 40.0 21.6
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Three years after the onset of skin thickening she de-
veloped pulmonary fibrosis that was treated with daily oral
ciclosporin and monthly i.v. pulses of CYC. Although her
FVC improved from 41% to 56%, 3 years later she con-
tinued to experience dyspnoea. At her most recent visit,
6 years after the onset of skin changes, there had been no
recurrence of her breast cancer. This patient’s presenta-
tion is also compatible with ANA-negative and RP-
negative SSc, although a paraneoplastic syndrome must
be considered.
Case 3
A 25-year-old white female with a history of palpitations
and FM noted thickening of the skin on her face and scler-
odactyly and was diagnosed as having limited SSc. No
cobblestone or peau d’orange changes were seen. She
never developed RP, pulmonary arterial hypertension or
pulmonary fibrosis, but she experienced oesophageal
reflux and dysphagia. She never suffered from pruritus
and denied any exposure to environmental toxins.
Nail-fold capillaroscopy showed an early SSc pattern
[13] but, over a period of 7 years, ANA testing has been
repeatedly negative. She has had no peripheral blood eo-
sinophilia or paraproteinaemia and had not undergone
any GCCA-enhanced MRI studies. A skin biopsy was
not performed. Her initial mRSS was 5, at which time
treatment with MTX and oral CSs was initiated and con-
tinued for the next 2 years. After 7 years of follow-up her
skin changes have remained stable. This patient’s pres-
entation is also compatible with ANA-negative and
RP-negative SSc.
Case 4
A 41-year-old white man experienced the onset of skin
thickening with symmetrical involvement of his arms and
legs and on his face and trunk. He did not suffer from
pruritus and denied toxin exposure. Five years later his
mRSS was 31. He exhibited severe flexion contractures
of his elbows, but he had normal renal function and re-
ported no prior gadolinium exposure. He experienced
FIG. 1 Nail-fold capillaroscopy and skin biopsy from case 1.
(a) A representative area from a technically difficult nail-fold capillaroscopy demonstrating the absence of a typical
scleroderma pattern in case 1. (b) Haematoxylin and eosin stain of a punch biopsy specimen from the abdominal skin of
case 1, showing severe dermal fibrosis and s.c. septae. Dermal capillaries are slightly hypotrophic and the s.c. fat is
diminished in the vicinity of the adnexae. (c) A higher magnification reveals a sparse perivascular lymphocytic inflam-
matory infiltrate without eosinophils.
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dysphagia, but he had no pulmonary fibrosis. Neither nail-
fold capillaroscopy nor skin biopsy was performed. He
had an IgG paraproteinaemia and was diagnosed with
multiple myeloma. He was treated with autologous stem
cell transplantation. Unfortunately he was subsequently
lost to follow-up. The development of cutaneous fibrosis
in the setting of paraproteinaemia makes scleromyxoe-
dema the most likely diagnosis.
Case 5
A 51-year-old white woman with a history of urothelial
bladder carcinoma, treated exclusively with surgery
4 years earlier, experienced the onset of sclerodactyly
and thickening of the skin on her face. Her skin sclerosis
progressed rapidly within a few months to also involve her
hands, feet, arms, legs and trunk. Her maximum mRSS at
that time was 37. On physical examination her skin was
thickened, hard to palpation and tightly adhered to deeper
tissues. The skin surface was uniform and without peau
d’orange or cobblestone appearance. Although she res-
ides in a cold climate, she never experienced RP. She
denied pruritus and had no known toxin exposure. Nail-
fold capillaroscopy was normal on two occasions. At
presentation she had peripheral blood eosinophilia
(800/ml, 10%) and elevation of her ESR to 37 mm/h.
Biopsy of skin from her forearm revealed no mucin, but
suggested eosinophilic fasciitis.
Because of symmetric pain and severe stiffness in her
hands, knees and feet that was most pronounced in the
morning but not accompanied by joint swelling, she was
treated with oral prednisone 10 mg daily, oral MTX up to
20 mg weekly and oral HCQ 400 mg daily. Her joint symp-
toms improved markedly with medical treatment and her
mRSS decreased to 18.
One year later she experienced a relapse of her bladder
carcinoma and treatment with MTX, prednisone and HCQ
was discontinued. Within 2 months of stopping these medi-
cations, her skin sclerosis worsened, at which time her
mRSS was 31, and she again experienced arthralgias and
morning stiffness. After surgery to treat her recurrent bladder
carcinoma, she was treated with oral D-Pen 500 mg daily and
prednisone therapy was reinitiated. Because she did not
note any improvement in her skin or joint symptoms, MTX
was restarted 6 months after surgery. Her articular symp-
toms improved and her mRSS decreased to 15.
Five years after her initial presentation there is still
no evidence of visceral involvement. Her mRSS has
decreased further to 10 and she experiences only mild
arthralgias and morning stiffness. Although some features
of this case are compatible with eosinophilic fasciitis [6],
the presence of sclerodactyly and facial involvement are
FIG. 2 Symmetrical skin thickening involving all parts of the body, sparing only the hands and feet (case 2).
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not consistent with that diagnosis. Thus another paraneo-
plastic syndrome must be considered.
Case 6
A 62-year-old white man with coronary artery disease,
hypertension and diabetes mellitus presented with cuta-
neous non-pruritic sclerosis and mRSS 17. Unfortunately
his medical records did not provide a more detailed de-
scription of his skin changes or the exact date of onset of
his skin changes. There was no history of toxin exposure.
He also experienced dysphagia and dyspnoea due to pul-
monary fibrosis and pulmonary hypertension. Neither a
skin biopsy nor nail-fold capillaroscopy was performed;
his specific diagnosis remains unknown. He subsequently
was not seen by a rheumatologist and he died 3 years
after his initial evaluation for the EUSTAR database. The
presence of pulmonary fibrosis and dysphagia are com-
patible with SSc, but not with either scleromyxoedema or
scleroedema adultorum of Buschke, which might be con-
sidered in the setting of his diabetes mellitus.
Discussion
In this study, 12 (0.2%) of 5390 patients in the EUSTAR
database who fulfilled the ACR criteria for SSc had neither
RP nor circulating ANA. Assuming the prevalence of RP to
be 98% [3] and that of circulating ANA to be 90%, based
on data from other SSc cohorts [2], our result corresponds
well with the calculated theoretical prevalence of
RP-negative and ANA-negative SSc [(10.98) (10.90)
= 0.2%].
Although all seven patients for whom detailed informa-
tion was available fulfilled the ACR criteria for SSc, an
unequivocal diagnosis of SSc could not be made in four
cases. The other three (cases 13) were compatible with
ANA-negative and RP-negative SSc and were not typical
of most known SSc mimics. We are aware of only one
other report of ANA-negative and RP-negative SSc [4]
occurring in the absence of malignancy. Our study has
identified additional cases of ANA-negative and
RP-negative SSc, but additional investigation is needed
to further characterize the clinical presentation, evolution
and outcome of this subset of SSc patients and to ascer-
tain whether this entity represents a discrete clinical
syndrome.
The diagnosis of a paraneoplastic syndrome must also
be considered when SSc presents without RP or circulat-
ing ANA; this is difficult to exclude completely in a retro-
spective analysis of a large database of patients who have
been enrolled at many different centres. The characteriza-
tion of SSc as a paraneoplastic syndrome is still not well
defined; it is questionable as to whether an association
between SSc and cancer truly exists. One report
described skin fibrosis without associated RP that de-
veloped in five patients with solid tumours: three with
lung cancer, one with breast cancer and one with undif-
ferentiated head and neck cancer [14]. Circulating ANAs
were detected in only two of the five patients. Serum basic
fibroblast growth factor (bFGF) levels were elevated in
these five patients with paraneoplastic SSc as compared
with both SSc patients and healthy controls; bFGF ex-
pression was up-regulated in the fibroblasts of affected
skin [14]. In the present study, four of the seven patients
for whom detailed information was available had a malig-
nancy (cases 1, 2, 4 and 5): two had breast cancer, one
had multiple myeloma and one had bladder carcinoma.
A fifth patient (case 6) died 3 years after his initial visit
without a recorded cause of death; thus he might also
have had a malignancy. In most cases where SSc de-
velops in the setting of malignancy, there is a close tem-
poral relationship between the onset of SSc and the
diagnosis of cancer [14, 15]. Because case 1 developed
breast cancer 10 years before the onset of her SSc and
her cancer had not reoccurred within 6 years after the
onset of her cutaneous and pulmonary fibrosis, it is un-
likely that her systemic fibrosis represented a true para-
neoplastic process.
Several studies have reported that breast, pulmonary,
urogenital, haematological, gastrointestinal and head and
neck malignancies occur more frequently in patients with
SSc as compared with the general population. Thus SSc
might be considered as a risk factor for the development
of cancer [1423]. However, unlike our analysis, these
studies did not attempt to differentiate SSc from its
mimics and classified patients with skin fibrosis using
only the ACR criteria for SSc [1517].
Our findings highlight the importance of conducting a
thorough clinical evaluation when SSc is suspected in the
absence of circulating ANA and RP. This assessment
should include a detailed history (including toxin expos-
ure) and a thorough clinical examination to assess the
anatomic distribution of skin sclerosis and the precise ap-
pearance of the skin (Table 1). The history should include
toxin exposure in terms of gadolinium, cleaning products,
organic solvents, formaldehyde, epoxy resins and silica
dusts [12]. We also suggest that nail-fold capillaroscopy,
serum immunoelectrophoresis, skin biopsy and CT of the
chest be performed as part of the routine evaluation of
these patients.
NSF is a relatively recently described fibrosing disorder
that may be underdiagnosed [24]. Although no case of
definite NSF was identified among the cases of
ANA-negative and RP-negative SSc in the EUSTAR data-
base, the clinical presentation of the 54-year-old woman
with multiple myeloma who underwent GCCA-enhanced
MRI about 4 weeks before the onset of skin changes
could be compatible with that of NSF, other than for the
absence of chronic kidney disease. Since the physicians
contributing cases to the EUSTAR database are experts in
fibrosing diseases, they may have been aware of NSF as a
distinct SSc mimic and not entered those cases into the
EUSTAR database.
Among the small number of patients who present with
cutaneous fibrosis in the absence of RP and circulating
ANA, some have ANA-negative and RP-negative SSc,
whereas others have atypical presentations of conditions
that are known to mimic SSc. The presence or the sub-
sequent development of a malignancy must be con-
sidered as a serious possibility in these patients;
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however, some cases ultimately cannot be classified into
known diagnostic entities.
Rheumatology key messages
. Some patients with an SSc phenotype lack ANAs
and RP.
. Unusual presentations of SSc require a thorough
differential diagnosis.
. Other causes of skin sclerosis must be strongly
considered in patients who have skin fibrosis but
lack ANA and RP.
Disclosure statement: The authors have declared no
conflicts of interest.
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